Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents;Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos: Recomendaciones de la Asociación Española de Gastroenterología y de la Sociedad Española de Reumatología

Gastroenterologia y Hepatologia

Volumn 26, Issue 8, 2003, Pages 485-502

  Lanas, A ^a   Martin Mola, E ^b   Ponce, J ^a   Navarro, F ^b   Pique J M ^a   Blanco, F J ^b  

^a Asoc Espanola de Gastroenterologia   (Spain)

^b UNIDAD DE INVESTIGACIÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; LORNOXICAM; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; STEROID; STOMACH SECRETION INHIBITOR; TENOXICAM; WARFARIN;

AGE; CLINICAL TRIAL; DRUG POTENTIATION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE POLICY; HUMAN; HYPERTENSION; MEDICAL SOCIETY; MUSCULOSKELETAL DISEASE; PEPTIC ULCER; PRACTICE GUIDELINE; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; STOMACH PROTECTION;

EID: 0142260431     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13051932     Document Type: Review

References (138)

1. Lanas A, Piqué JM, Ponce J. Estrategia clínica para el paciente que precisa antiinflamatorios no esteroides: posición de los inhibidores de la COX-2. Gastroenterol Hepatol 2001;24:22-36.
2. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
3. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241-9.
4. Hernández-Díaz S, García Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal antiinflmmatory drugs. Am J Med 2001 (Suppl);110:S20-7.
5. Laine L, Bombardier C, Hawkey C, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
6. Messer J, Reitman D, Sacks HS, Smith H, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:619-32.
7. Conn H, Poynard T. Corticosteroids and peptic ulcer: metaanalysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
8. Hernández-Díaz S, García Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001; 153:1089-93.
9. García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetamonophen, and combinations of these agents. Arthritis Res 2001;3:98-101.
10. Johnsen SP, Sorensen HT, Mellemkjoer L, Blot WJ, Nielsen GL, McLaughlin JK, et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 2001;86:563-8.
11. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, et al Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
12. Schorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nosteroidal antiinnflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorragic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
13. Knifff-Dutmer EAJ. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacoth 2003;37:12-6.
14. Pardo A, Garcia-Losa M, Fernandez-Pavon A, Del Castillo S, Pascual-García T, et al. A placebo controlled stady of interaction between nabumetone and acenocoumarol. Br J Clin Pharmacol 1999;47:441-4.
15. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.
16. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
17. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995;29:1274-83.
18. Van Hecken A, Schwartz JI, Depré M, Lepeleire I, Dallob A, Tanaka L, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40: 1109-20.
19. Karim A, Tolbert D, Piergies A, Hubbard RC, Harper K, Wallemark CB, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprotrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000;40:655-63.
20. Knijff-Dutmer EA, Martens A, Van der Laar MA. Effects of Nabumetone compared with Naprosen on platelet agregation in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58:257-9.
21. Buvanendran A, Elmofty D, Tuman KJ, Scheinkop M, Kroin JS. Administration of selective cyclooxygenase-2 inhibitor with warfarin does not increase blood loss following total knee arthroplasty (TKA). Anesthesiology 2002;96:A-942.
22. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Am J Dig Dis 1983;28:1-6.
23. Skeljo MV, Cook GA, Elliot SL, Giraud AS, Yeomans ND. Gastric mucosal adaptation to diclofenac injury. Dig Dis Sci 1996;41:32-9.
24. Stachura J, Konturek JW, Dembinski A, Domschke W. Growth markers in the human gastric mucosa during adaptation to continued aspirin administration. J Clin Gastroenterol 1996;22:282-7.
25. Hernández-Díaz S, García Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000; 160:2093-9.
26. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998;114:245-55.
27. Lipscomb GR, Campbell F, Rees WD. The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal antinflammatory drugs. Aliment Pharmacol Ther 1997;11:907-12.
28. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:18-24.
29. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-88.
30. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
31. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
32. García Rodríguez LA, Cattaruzzi CH, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolack, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
33. Laporte JR, Carné X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesic and non-steroidal anti-inflammatory drugs. Lancet 1991;1:85-9.
34. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
35. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:438-44.
36. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
37. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-30.
38. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996;28:204-10.
39. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-9.
40. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
41. Imhof M, Ohmann C, Hartwig A, Thon KP, Hengels KJ, Roher HD. Which peptic ulcers bleed? Results of a case-control study. DUSUK Study Group. Scand J Gastroenterol 1997;32: 131-8.
42. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
43. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, Van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26.
44. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
45. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs. Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169-75.
46. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
47. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
48. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996;28:204-10.
49. Santolaria S, Lanas A, Benito R, Pérez-Aisa MA, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13:1511-8.
50. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999;116:1305-9.
51. Cullen DJ, Hawkey GM, Greenwood DC, Humphreys H, Shepherd V, Logan RF, et al Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997;41:459-62.
52. Wu CY, Poon SK, Chen GH, Chang CS, Yeh HZ. Interaction between Helicobacter pylori and nonsteroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol 1998;33:234-7.
53. Pilotto A, Leandro G, Di Mario F, Franceschi M, Bozzola L, Valerio G. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly. A case-control study. Dig Dis Sci 1997;42:586-91.
54. Labenz J, Peitz U, Köhl H, Kaiser J, Malfertheiner P, Hackelsberger A, et al. Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study. Ital J Gastroenterol Hepatol 1999;31:110-5.
55. Ng TM, Fock KM, Khor JL, Teo EK, Sim CS, Tan AL, et al. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Aliment Pharmacol Ther 2000;14: 203-9.
56. Hawkey CJ. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 2000;46:310-1.
57. Li EK, Sung JJ, Suen R, Ling TK, Leung VK, Hui E, et al. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. Scand J Rheumatol 1996;25:42-6.
58. Pilotto A, Franceschi M, Leandro G, Di Mario F, Valerio G. The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. Eur J Gastroenterol Hepatol 1997;9:951-6.
59. Taha AS, Sturrock RD, Russell RI. Mucosal erosions in long-term non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut 1995;36:334-6.
60. Janssen M, Dijkmans BA, Lamers CB, Zwinderman AH, Vandenbroucke JP. A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol 1994;33:449-59.
61. Kim JG, Graham DY, and The Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 1994;89:203-7.
62. Voutilainen M, Sokka T, Juhola M, Farkkila M, Hannonen P. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Scand J Gastroenterol 1998;33:811-6.
63. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
64. Bianchi Porro G, Parente F, Imbasi V, Montrone F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy. Gut 1996;39:22-6.
65. Hawkey CJ, Tulassay Z, Szczepanski L, Van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study Lancet 1998;352:1016-21.
66. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002;359:14-22.
67. Labenz J, Blum AL, Bolten WW, Dragosics B, Rosch W, Stolte M, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-35.
68. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interaction between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-506.
69. Laine L. Review article: the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther 2002; 16(Suppl 1):34-9.
70. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther 2001;15:63-71.
71. Ko CW, Deyo RA. Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease. J Gen Intern Med 2000;15:400-10.
72. Hawkey CJ, Wilson I, Naesdal J, Langstrom G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 2002;51:344-50.
73. Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang B, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002;97:2208-14.
74. Calvet X, Gratacos J, Font J, Larrosa M, Sanfeliu I, Roque M. Helicobacter pylori does not play a part in the dyspeptic complaints of rheumatology patients receiving long term treatment with non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2002;61:641-3.
75. Bannwarth B, Dorval E, Caekaert A, Barthelemy P. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. J Rheumatol 2002;29:1975-80.
76. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7.
77. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002;16:1945-53.
78. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
79. Goldstein JL, Eisen G, Bensen W. SUCCESS in osteoarthritis (OA) trial: celecoxib significantly reduces the risk of upper gastrointestinal (UGI) hospitalizations compared to diclofenac and naproxen in 13,274 randomized patients with OA [abstract]. Presented at: European League Against Rheumatism; Prague; June 13-16, 2001.
80. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao P, Quan HH, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
81. Geba GP, Polis AB, Skalky CS, Petruschke RA, Dobbins TW. Rofecoxib versus naproxen in osteoarthritis patients receiving concomitant low dose aspirin: a subgroup analysis involving 719 patients fron the ADVANTAGE trial. European League Against Rheumatism; Stockholm, June 12-15, 2002.
82. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619.
83. Lanas A, Sekar MC, Hirschowitz BI. Objetive evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992;103:862-9.
84. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:990-7.
85. Smecuol E, Bai JC, Sugai E, Vázquez H, Niveloni S, Pedreira S, et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001;49:650-5.
86. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-32.
87. Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201-6.
88. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
89. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3:383-8.
90. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, De Marco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2002;345:1089-17.
91. Lanas A, Serrano P, Bajador E, Fuentes J, Sáinz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2003;15:1-6.
92. Matias-Guiu J, Ferro J, Álvarez-Sabín J, Torres F. Triflusal versus aspirin in secondary stroke prevention: results of TACIP study [abstract 73]. Stroke 2001;32:329.
93. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic event (CAPRIE). Lancet 1996;348:1329-39.
94. Sheikh RA, Romano PS, Prindiville TP, Yasmeen S, Trudeau W. Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls. J Clin Gastroenterol 2002;34:529-32.
95. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. Randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-7.
96. Ruggeri M, Castaman G, Rodeghiero F. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica 1993;78(6 Suppl 2):18-21.
97. Forrest JB, Camu F, Greer IA, Kehlet H, Abdalla M, Bonnet F, et al. Ketorolac, Diclofenac and Ketoprofen are equally safe for pain relief after major surgery. Br J Anesthesia 2002; 88:227-33.
98. Langman MJS. Risks of antiinflammatory drug-associated damage. Inflamm Res 1999;48:236-8.
99. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002;89:D3-9.
100. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxigenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. PNAS 2001;98:14583-8.
101. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of Celecoxib, a novel cyclooxigenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-32.
102. Depré M, Ehrich EW, Van Hencken A, Lepeleire I, Dallob A, Wong P. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000;56:167-74.
103. Reuben SS, Connelly NR. Postoperative analgesic effects of Celecoxib or Rofecoxib after spinal fusion surgery. Anesth Analg 2000;91:1221-5.
104. Edwards JE, Meseguer F, Faura CC, Moore RA, McQuay HJ. Single-dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 2001;3:CD003227.
105. Bianchi Porro G, Ardizzone S, Petrillo M, Caruso I, Montrone F. Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. Digestion 1996;57:186-90.
106. Sánchez S, Martín MJ, Ortíz P, Motilva V, Alarcón de la Lastra C. Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa. Dig Dis Sci 2002; 47:1389-98.
107. Lanas A, Serrano P, Bajador E, Fuentes J, Sáinz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2003;15:1-6.
108. Flower RJ, Vane JR. Inhibition of prostaglandin synthase in brain explains the anti-pyrectic activity of paracetamol. Nature 1972;240:410-1.
109. Lanza FL, Codispoti JR, Nelson EB. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketaprofen and acetominophen. Am J Gastroenterol 1998;93: 1051-4.
110. Jerussi TP, Caubet JF, McCray JE, Handley DA. Clinical endoscopic evaluation of the gastroduodenal tolerance to R-ketoprofen, R-flubirprofen, racemic ketoprofen and paracetamol: a randomized, single-blind, placebo-controlled trial. J Clin Pharmacol 1998;38(Suppl):S19-24.
111. Muller P, Simon B, Weise D, Dammann HG. Endoscopic studies on the gastric tolerance of paracetamol and acetylsalicylic acid: a placebo-controlled, double-blind study in healthy volunteers. Arzneimittelforschung 2000;40:316-8.
112. Moore AR, Van Gansen E, Le Parc JM, Wall R, Scheid H, Farhan M, et al. The PAIN study: paracetamol, aspirin, ibuprofen new tolerability. A large scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short term analgesia. Clin Drug Invest 1999;18:89-98.
113. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of iburpfen, and analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87-91.
114. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Osteoarthritis of the Knee. JAMA 2002;287:64-71.
115. Silverfield JC, Kamin M, Wu SC, Rosenthal N, and CAPSS-105 Study Group. Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther 2002;24:282-97.
116. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis & Rheum 2002;46:3046-54.
117. García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
118. Werner MU, Nielsen PR, Romsing J, García Rodríguez LA, Hernández-Díaz S. Acetaminophen and upper gastrointestinal complications. Epidemiology 2002;13:605-7.
119. Pincus T, Koch G, Sokka T, Lefkowith J, Wolfe F, Jordan JM, et al. A randomised, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001;44:1587-98.
120. Rampal P, Moore N, VanGanse E, La Parc JM, Wall R, Schneid H, et al. Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses. J Int Med Res 2002;30:301-8.
121. Graham DY, Smith JL. Effects of aspirin and an aspirin-acetaminophen combination on the gastric mucosa in normal subjects. A double-blind endoscopic study. Gastroenterology 1985;88:1922-5.
122. Stern AI, Hogan DL, Kahn LH, Isenberg JI. Protective effect of acetaminophen against aspirin- and ethanol-induced damage to the human gastric mucosa. Gastroenterology 1984;86: 728-33.
123. Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract. Indigestion and non-steroidal anti-inflammatory drugs. BMJ 2001;323:1236-9.
124. Hardo PG, Chalmers DM, Jakeways M, Wright V, Axon ATR. Management of NSAIDs-related dyspepsia in the community. Br J Clin Pract 1993;47:241-2.
125. Van Groenendael JH, Markusse HM, Dijkmans BA, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Reumatol 1996;15:450-6.
126. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenla ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9.
127. Ekström P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O. Prevention of peptic ulcer and dispeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996;31:753-8.
128. Agrawal NM, Campbell DR, Safdi MA, Likasik NL, Huang B, Hhaber MM, and NSAIDs-Associated Gastric Ulcer Study Group. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med 2000;160:1455-61.
129. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). The Cochrane Library, Issue 3. Oxford: Update Software, 2001.
130. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double.blind, multicenter study. Am J Gastroenterol 1996;91:223-7.
131. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
132. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Inter Med 1996;156: 1530-6.
133. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA, et al. Do NSAIDs cause dyspepsia?. A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002;97:1951-8.
134. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxigenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitor in osteoarthritis. Arch Intern Med 2000;160:2998-3003.
135. Rabeneck L, Wristers K, Goldstein JL, Eisen G, Dedhiya SD, Burke TA. Reliability, validity, and responsiveness of severity of dyspesia assessment (SODA) in a randomized clinical trial of a COX-2-especific inhibitor and traditional NSAID therapy. Am J Gastroenterol 2002;97:32-9.
136. Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Reumathol 2000;27:1876-83.
137. Geba GP, Polis AB, Skalky CS, Petruschke RA, Dobbins TW. Rofecoxib versus naproxen in osteoarthritis patients receiving concomitant low dose aspirin: A subgroup analysis involving 719 patients fron the ADVANTAGE trial. European League Against Rheumatism; Stockholm, June 12-15, 2002.
138. Hsu PI, Lai KKH, Lo GH, Tseng HH, Lo CC, Chen HC, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002;51:15-20.